Intuitive Surgical (ISRG) Q4 2025 earnings review
da Vinci 5 Supercycle masked by Tariff and Ion Headwinds
Intuitive closed FY25 with a robust 19% revenue increase, driven by an aggressive adoption of the new da Vinci 5 (dV5) system, which now accounts for 57% of all placements. However, beneath the headline beat lies a mixed picture. While the surgical robot upgrade cycle is accelerating, the Ion lung biopsy platform saw a sharp 39% drop in system placements, suggesting saturation or capital constraints. Looking ahead to FY26, guidance calls for a deceleration in procedure growth (13-15%) and a 1.2% margin drag from tariffs, signaling that the easy post-COVID growth comparisons are over.
🐂 Bull Case
Adoption of the new flagship system is accelerating rapidly. dV5 placements ramped from 147 in Q1 to 303 in Q4, now comprising 57% of total systems. This drives higher ASPs and locks in customers for the next decade.
Recurring revenue (instruments, accessories, services) hit 81% of total revenue. Even if capital sales slow, the massive installed base (11,106 systems, +12%) ensures predictable cash flow.
🐻 Bear Case
Ion system placements collapsed 39% YoY (42 vs 69). While procedure volume is up, the sharp drop in hardware sales suggests the 'greenfield' opportunity for robotic bronchoscopy may be saturating faster than expected.
Management guided FY26 procedure growth to 13-15%, a clear step down from the 18% growth seen in FY25. Combined with a 120bps gross margin headwind from tariffs, earnings leverage will be harder to come by.
⚖️ Verdict: ⚪
Neutral/Hold. The dV5 launch is a operational triumph, but the valuation leaves no room for error. The sudden drop in Ion placements and the margin drag from tariffs warrant caution until FY26 growth normalizes.
Key Themes
The da Vinci 5 Takeover
Accelerating. The transition to the new dV5 platform is happening faster than previous cycles. In Q4, dV5 represented 303 out of 532 total placements (57%), up from just ~8 placements in Q1 2024. This mix shift is driving higher System Revenue ($786M, +20% YoY) despite a relatively flat total placement count vs historic highs.
Ion Placements Collapse
Reversing. While Ion procedure volume grew 44%, capital placements for the lung biopsy system fell significantly to 42 units in Q4, down from 69 a year ago and 50 in Q3. This -39% YoY drop is a red flag that the easy capital wins in the U.S. market may be exhausted, forcing a shift to a harder 'utilization' sales motion.
Tariffs Impacting Margins
Stable/Negative. Management explicitly quantified the tariff pain for FY26: an estimated 1.2% drag on revenue (approx. $120M+ impact). This suppresses Non-GAAP Gross Margins to a guided range of 67-68%, effectively capping margin expansion despite the high-ASP dV5 product cycle.
Leasing Mix Normalizing
Stable. The usage-based leasing model remains a key tool but isn't aggressively expanding. In Q4, 150 da Vinci systems were placed under usage-based leases vs 140 a year ago. The proportion of recurring revenue held steady at roughly 80-81%, maintaining the company's defensive profile.
Other KPIs
Accelerating slightly (+17% YoY). This high-margin line item tracks procedure volume closely. With dV5's advanced instrumentation (Force Feedback) likely carrying higher ASPs, this segment should remain durable even if procedure volume growth moderates to the guided 13-15% range.
Stable. Up $200M from Q3 ($8.83B) despite continued CAPEX and likely buybacks (though Q4 buyback data was not explicitly detailed in the summary, cash flow from operations remains robust enough to fund operations and inventory build).
Stable (+12% YoY). The base is massive. The key metric to watch is the retirement of older S and Si models (22 retired in Q4), which accelerates the replacement cycle to dV5.
Guidance
Decelerating. This is a marked slowdown from the 18% growth achieved in FY25 and 17% in FY24. It suggests the post-COVID backlog flush is over and the law of large numbers is taking effect on the 3M+ annual procedure base.
Stable/Compressed. FY25 Non-GAAP GM was 67.6%. The guide implies margins will remain flat or compress slightly due to the 1.2% tariff headwind, despite the accretive mix of dV5 system sales.
Stable. Consistent with the 12% growth seen in FY25. Management is not pulling back on R&D or Sales expansion despite the tariff headwinds, signaling confidence in the long-term dV5 and Ion opportunities.
Key Questions
Ion Placement Drop
Ion system placements fell 39% YoY in Q4. Is this purely a function of capital budget constraints in US hospitals, or have we reached saturation in the Tier 1 academic centers?
Tariff Mitigation Timeline
You've baked in a 1.2% tariff impact for FY26. What specific supply chain adjustments (e.g., Mexico manufacturing shifts) are underway, and when might these actions start to offset the gross margin drag?
Procedure Guidance Conservatism
FY26 procedure guidance (13-15%) represents a material deceleration from FY25 (18%). Are you seeing specific weakness in bariatrics or benign general surgery, or is this primarily conservatism regarding China/OUS markets?
da Vinci 5 ASP & Margins
With dV5 now at 57% of placements, how are the initial gross margins of these units comparing to mature Xi margins, and how quickly will manufacturing efficiencies bridge the gap?